Results 141 to 150 of about 24,697,135 (341)

Evolution of the immune system in humans from infancy to old age

open access: yesProceedings of the Royal Society B: Biological Sciences, 2015
This article reviews the development of the immune response through neonatal, infant and adult life, including pregnancy, ending with the decline in old age.
Anna Katharina Simon   +2 more
semanticscholar   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

open access: yesMolecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez   +17 more
wiley   +1 more source

Mercury and its toxic effects on fish

open access: yesAIMS Environmental Science, 2017
Mercury (Hg) and its derivative compounds have been parts of widespread pollutants of the aquatic environment. Since Hg is absorbed by fish and passed up the food chain to other fish-eating species, it does not only affect aquatic ecosystems but also ...
Patricia Morcillo   +2 more
doaj   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

open access: yesMolecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

The Dynamics of the Skin’s Immune System

open access: yesInternational Journal of Molecular Sciences, 2019
The skin is a complex organ that has devised numerous strategies, such as physical, chemical, and microbiological barriers, to protect the host from external insults.
Alan V Nguyen, A. Soulika
semanticscholar   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

open access: yesMolecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma   +9 more
wiley   +1 more source

A Study of Immunologic Tolerance in the Dinitrophenyl Poly-l-Lysine Immune System [PDF]

open access: bronze, 1969
Gail A. Theis   +3 more
openalex   +1 more source

An aged immune system drives senescence and ageing of solid organs

open access: yesNature, 2021
Matthew J. Yousefzadeh   +32 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy